Logo image of LBPS

4D Pharma PLC (LBPS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LBPS - US35085K1097 - ADR

1.65
+0.04 (+2.48%)
Last: 6/24/2022, 8:00:03 PM
Fundamental Rating

1

Overall LBPS gets a fundamental rating of 1 out of 10. We evaluated LBPS against 191 industry peers in the Pharmaceuticals industry. LBPS has a bad profitability rating. Also its financial health evaluation is rather negative. LBPS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LBPS has reported negative net income.
LBPS Yearly Net Income VS EBIT VS OCF VS FCFLBPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA -125.66%
ROE N/A
ROIC -55.1%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LBPS Yearly ROA, ROE, ROICLBPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -50 -100 -150 -200

1.3 Margins

The Operating Margin and Gross Margin are not available for LBPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -10376.92%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LBPS Yearly Profit, Operating, Gross MarginsLBPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -5K -10K

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LBPS is destroying value.
Compared to 1 year ago, LBPS has more shares outstanding
LBPS has a worse debt/assets ratio than last year.
LBPS Yearly Shares OutstandingLBPS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M
LBPS Yearly Total Debt VS Total AssetsLBPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

LBPS has an Altman-Z score of -8.18. This is a bad value and indicates that LBPS is not financially healthy and even has some risk of bankruptcy.
LBPS has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Altman-Z -8.18
ROIC/WACC-5.29
WACC10.41%
LBPS Yearly LT Debt VS Equity VS FCFLBPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 5.21 indicates that LBPS has no problem at all paying its short term obligations.
A Quick Ratio of 5.16 indicates that LBPS has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 5.21
Quick Ratio 5.16
LBPS Yearly Current Assets VS Current LiabilitesLBPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

LBPS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.21%.
Looking at the last year, LBPS shows a decrease in Revenue. The Revenue has decreased by -3.70% in the last year.
EPS 1Y (TTM)-43.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.97%
Revenue 1Y (TTM)-3.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.54%

3.2 Future

LBPS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.36% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.11%
EPS Next 2Y-10.93%
EPS Next 3Y-11.78%
EPS Next 5Y-0.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LBPS Yearly Revenue VS EstimatesLBPS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 5M 10M 15M
LBPS Yearly EPS VS EstimatesLBPS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LBPS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LBPS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LBPS Price Earnings VS Forward Price EarningsLBPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.99
LBPS Per share dataLBPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

LBPS's earnings are expected to decrease with -11.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.93%
EPS Next 3Y-11.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LBPS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4D Pharma PLC

NASDAQ:LBPS (6/24/2022, 8:00:03 PM)

1.65

+0.04 (+2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2022-03-31/amc
Earnings (Next)09-28 2022-09-28
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap37.19M
Revenue(TTM)520.00K
Net Income(TTM)-53.96M
Analysts80
Price Target7.52 (355.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 59.44
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB N/A
EV/EBITDA -0.99
EPS(TTM)-3.24
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS1.24
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -125.66%
ROE N/A
ROCE N/A
ROIC -55.1%
ROICexc N/A
ROICexgc -86.07%
OM N/A
PM (TTM) -10376.92%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.21
Quick Ratio 5.16
Altman-Z -8.18
F-Score2
WACC10.41%
ROIC/WACC-5.29
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.97%
EPS Next Y-7.11%
EPS Next 2Y-10.93%
EPS Next 3Y-11.78%
EPS Next 5Y-0.36%
Revenue 1Y (TTM)-3.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

4D Pharma PLC / LBPS FAQ

What is the ChartMill fundamental rating of 4D Pharma PLC (LBPS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to LBPS.


What is the valuation status of 4D Pharma PLC (LBPS) stock?

ChartMill assigns a valuation rating of 1 / 10 to 4D Pharma PLC (LBPS). This can be considered as Overvalued.


Can you provide the profitability details for 4D Pharma PLC?

4D Pharma PLC (LBPS) has a profitability rating of 0 / 10.


How financially healthy is 4D Pharma PLC?

The financial health rating of 4D Pharma PLC (LBPS) is 2 / 10.